Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496836 | 0.93 | S1PR4 (0.32) | FDPSGGPS1 | |
| Phosphoric Acid SCHEMBL11085351 | 0.71 | S1PR1 (0.36) | FDPSGGPS1LPAR1LPAR3 | |
| SCHEMBL8153101 | 0.69 | — | — | |
| SCHEMBL5346241 | 0.68 | SMPD1 (0.37) | FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL11085353 | 0.68 | INPP5A (0.41) | FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL8207495 | 0.67 | FDPS (0.45) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL8149004 | 0.67 | — | — | |
| SCHEMBL8154749 | 0.67 | FDPS (0.37) | FDPS | |
| SCHEMBL8140433 | 0.67 | FDPS (0.37) | FDPS | |
| Phosphoric Acid SCHEMBL11084348 | 0.66 | S1PR4 (0.39) | FDPSLPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106032-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2012-01-31 | — | — | US | claimed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | claimed |
| EP-0781138-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1997-07-02 | — | — | EP | claimed |
| WO-1996006620-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1996-03-07 | — | — | WO | claimed |
| US-8106032-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7294621-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294620-B2 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294619-B2 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1852121-A2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070105811-A1 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-20070099870-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY | 2007-05-03 | — | — | US | disclosed |
| US-7141557-B2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-11-28 | — | — | US | disclosed |
| US-7135584-B2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7129227-B1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050080050-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040259845-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY | 2004-12-23 | — | — | US | disclosed |
| US-5962437-A | HEPATITIS, HERPES AND AIDA VIRUS | WAKE FOREST UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | SGMS1, HDLBP, LIPC | FDPS 288/4885GGPS1 114/4885SMPD1 10/4885 |
| US-20070105811-A1 | Lipid analogs for inhibiting the activity of hepatitis B antigen | LIPC, APOB, PNLIP | FDPS 515/4885GGPS1 269/4885SMPD1 19/4885 |
| US-20040259845-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | FDPS 236/4885GGPS1 104/4885SMPD1 12/4885 |
| US-20050080050-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | FDPS 236/4885GGPS1 104/4885SMPD1 12/4885 |
| US-20080293667-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | FDPS 330/4885GGPS1 193/4885SMPD1 10/4885 |
| US-20070099870-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | FDPS 330/4885GGPS1 193/4885SMPD1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.